Movement Disorder Society – Clinical Diagnostic Criteria for Progressive Supranuclear Palsy
Objective: The International Parkinson and Movement Disorders Society-endorsed PSP Study Group aimed to provide an evidence- and consensus-based revision of the clinical diagnostic criteria for…Dynamic Instability and Stride Width in Parkinsonism
Objective: To compare differences in local dynamic stability (LDS) and its association with stride width in individuals with idiopathic Parkinson’s Disease (iPD), individuals with frontal…Results of a Phase 1, Single Ascending Dose, Placebo-Controlled Study of ABBV-8E12 in Patients with Progressive Supranuclear Palsy and Phase 2 Study Design
Objective: To present the results of a phase 1 study of ABBV-8E12 in subjects with Progressive Supranuclear Palsy (PSP) and design of a phase 2…Parkinsonism through astrocytic GABA induce motor symptoms
Objective: Although reactive gliosis is a prominent feature of PD, its role in pathogenesis has remained elusive. Here we show that aberrantly synthesized GABA from reactive astrocytes tonically inhibits neighboring dopaminergic neuronal firing in SNpc, reducing dopamine production and release, leading to parkinsonian motor symptoms. Background: Parkinsonism is a clinical syndrome of movement abnormalities seen in Parkinson’s disease (PD), which has been attributed to cell-autonomous mechanism of doparminergic neuronal death in the substantia nigra pars compacta (SNpc). Methods: To identify the…Semiquantitative analyses of DAT-SPECT imaging with an automated striatal analysis software in differential diagnosis of neurodegenerative parkinsonism
Objective: We investigate the usefulness Dopamine transporter (DAT)-SPECT with an automated striatal analysis software in differential diagnosis of neurodegenerative parkinsonism. Background: DAT-SPECT imaging is sensitive…Are a „mathematical brain“ and early childhood adverse events possible risk factors that contribute to Progressive Supranuclear Palsy?
Objective: To evaluate possible risk factors for the development of Progressive Supranuclear Palsy (PSP). Background: Risk factors for the development of neurodegenerative brain disorders are…Metabolomics study in a group of Parkinson’s disease patients from Northern India
Objective: To do (1) H NMR study in a group of Parkinson’s disease patients, disease controls, viz. multiple system atrophy (MSA) and progressive supra nuclear…Neurogenic bladder in progressive supranuclear palsy: A comparison with Parkinson’s disease and multiple system atrophy
Objective: To compare the features of urinary dysfunction in Progressive supranuclear palsy (PSP) with those of idiopathic Parkinson’s disease (IPD) and multiple system atrophy (MSA). Background:…Rolipram, a PDE-IV inhibitor protects against experimental Parkinsonism in mice
Objective: Rolipram, a specific inhibitor of the phosphodiesterase IV (PDE IV), has recently been shown to exert neuroprotective effects in an Alzheimer transgenic mouse model…Neuropsychiatric and Cognitive Predictors of Early Diagnosis of Progressive Supranuclear Palsy
Objective: To define differences of neuropsychiatric and neuropsychological profile among Progressive Supranuclear Palsy (PSP) -Richardson syndrome (PSP-RS), PSP-parkinsonism (PSP-P), and Parkinson’s disease (PD), in order…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.